Home > > > > > Report Detail

Psoriatic Arthritis - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Psoriatic Arthritis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Psoriatic Arthritis epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Psoriatic Arthritis Understanding and Treatment Algorithm

The market report provides the overview of the Psoriatic Arthritis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Psoriatic Arthritis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Psoriatic Arthritis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Psoriatic Arthritis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Psoriatic Arthritis Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Psoriatic Arthritis market.

Psoriatic Arthritis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Psoriatic Arthritis Report Insights

- Patient Population in Psoriatic Arthritis

- Therapeutic Approaches in Psoriatic Arthritis

- Psoriatic Arthritis Pipeline Analysis

- Psoriatic Arthritis Market Size and Trends

- Psoriatic Arthritis Market Opportunities

- Impact of upcoming Therapies in Psoriatic Arthritis

Psoriatic Arthritis Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Psoriatic Arthritis Report Assessment

- Current Treatment Practices in Psoriatic Arthritis

- Unmet Needs in Psoriatic Arthritis

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Psoriatic Arthritis market

- Organize sales and marketing efforts by identifying the best opportunities for Psoriatic Arthritis market

- To understand the future market competition in the Psoriatic Arthritis market.

Psoriatic Arthritis - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Psoriatic Arthritis Market Overview at a Glance
2.1. Market Share Distribution of Psoriatic Arthritis in 2016
2.2. Market Share Distribution of Psoriatic Arthritis in 2028
3. Disease Background and Overview: Psoriatic Arthritis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Psoriatic Arthritis in 7MM
4.3. Total Prevalent Patient Population of Psoriatic Arthritis in 7MM - By Countries
5. Epidemiology of Psoriatic Arthritis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.1.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.1.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.1.5. Diagnosed Cases of the Psoriatic Arthritis
5.1.6. Treatable Cases of the Psoriatic Arthritis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.4.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.4.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.4.5. Diagnosed Cases of the Psoriatic Arthritis
5.4.6. Treatable Cases of the Psoriatic Arthritis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.5.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.5.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.5.5. Diagnosed Cases of the Psoriatic Arthritis
5.5.6. Treatable Cases of the Psoriatic Arthritis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.6.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.6.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.6.5. Diagnosed Cases of the Psoriatic Arthritis
5.6.6. Treatable Cases of the Psoriatic Arthritis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.7.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.7.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.7.5. Diagnosed Cases of the Psoriatic Arthritis
5.7.6. Treatable Cases of the Psoriatic Arthritis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.8.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.8.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.8.5. Diagnosed Cases of the Psoriatic Arthritis
5.8.6. Treatable Cases of the Psoriatic Arthritis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Psoriatic Arthritis
5.9.3. Sub-Type Specific cases of the Psoriatic Arthritis *
5.9.4. Sex- Specific Cases of the Psoriatic Arthritis *
5.9.5. Diagnosed Cases of the Psoriatic Arthritis
5.9.6. Treatable Cases of the Psoriatic Arthritis
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Psoriatic Arthritis
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Psoriatic Arthritis
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Psoriatic Arthritis : 7MM Market Analysis
12.1. 7MM Market Size of Psoriatic Arthritis
12.2. 7MM Percentage Share of drugs marketed for Psoriatic Arthritis
12.3. 7MM Market Sales of Psoriatic Arthritis by Products
13. Psoriatic Arthritis : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Psoriatic Arthritis in United States
13.1.2. Percentage Share of drugs marketed for Psoriatic Arthritis in United States
13.1.3. Market Sales of Psoriatic Arthritis by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Psoriatic Arthritis in Germany
13.2.1.2. Percentage Share of drugs marketed for Psoriatic Arthritis in Germany
13.2.1.3. Market Sales of Psoriatic Arthritis by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Psoriatic Arthritis in France
13.2.2.2. Percentage Share of drugs marketed for Psoriatic Arthritis in France
13.2.2.3. Market Sales of Psoriatic Arthritis by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Psoriatic Arthritis in Italy
13.2.3.2. Percentage Share of drugs marketed for Psoriatic Arthritis in Italy
13.2.3.3. Market Sales of Psoriatic Arthritis by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Psoriatic Arthritis in Spain
13.2.4.2. Percentage Share of drugs marketed for Psoriatic Arthritis in Spain
13.2.4.3. Market Sales of Psoriatic Arthritis by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Psoriatic Arthritis in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Psoriatic Arthritis in United Kingdom
13.2.5.3. Market Sales of Psoriatic Arthritis by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Psoriatic Arthritis in Japan
13.3.2. Percentage Share of drugs marketed for Psoriatic Arthritis in Japan
13.3.3. Market Sales of Psoriatic Arthritis by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Psoriatic Arthritis in 7MM
Table 2: Total Prevalent/Incident Cases of the Psoriatic Arthritis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Psoriatic Arthritis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Psoriatic Arthritis in United States (2016-2028)
Table 5: Sex- Specific Cases of the Psoriatic Arthritis in United States (2016-2028)
Table 6: Diagnosed Cases of the Psoriatic Arthritis in United States (2016-2028)
Table 7: Treatable Cases of the Psoriatic Arthritis in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Psoriatic Arthritis in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Psoriatic Arthritis in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Psoriatic Arthritis in Germany (2016-2028)
Table 11: Diagnosed Cases of the Psoriatic Arthritis in Germany (2016-2028)
Table 12: Treatable Cases of the Psoriatic Arthritis in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Psoriatic Arthritis in France (2016-2028)
Table 14: Sub-Type Specific cases of the Psoriatic Arthritis in France (2016-2028)
Table 15: Sex- Specific Cases of the Psoriatic Arthritis in France (2016-2028)
Table 16: Diagnosed Cases of the Psoriatic Arthritis in France (2016-2028)
Table 17: Treatable Cases of the Psoriatic Arthritis in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Psoriatic Arthritis in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Psoriatic Arthritis in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Psoriatic Arthritis in Italy (2016-2028)
Table 21: Diagnosed Cases of the Psoriatic Arthritis in Italy (2016-2028)
Table 22: Treatable Cases of the Psoriatic Arthritis in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Psoriatic Arthritis in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Psoriatic Arthritis in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Psoriatic Arthritis in Spain (2016-2028)
Table 26: Diagnosed Cases of the Psoriatic Arthritis in Spain (2016-2028)
Table 27: Treatable Cases of the Psoriatic Arthritis in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Psoriatic Arthritis in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Psoriatic Arthritis in UK (2016-2028)
Table 30: Sex- Specific Cases of the Psoriatic Arthritis in UK (2016-2028)
Table 31: Diagnosed Cases of the Psoriatic Arthritis in UK (2016-2028)
Table 32: Treatable Cases of the Psoriatic Arthritis in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Psoriatic Arthritis in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Psoriatic Arthritis in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Psoriatic Arthritis in Japan (2016-2028)
Table 36: Diagnosed Cases of the Psoriatic Arthritis in Japan (2016-2028)
Table 37: Treatable Cases of the Psoriatic Arthritis in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 42:7MM- Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 45: United States-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 48: Germany-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 51: France-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 54: Italy-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 57: Spain-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 60:UK-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Table 63: Japan-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Psoriatic Arthritis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Psoriatic Arthritis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Psoriatic Arthritis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Psoriatic Arthritis in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Psoriatic Arthritis in United States (2016-2028)
Figure 6: Diagnosed Cases of the Psoriatic Arthritis in United States (2016-2028)
Figure 7: Treatable Cases of the Psoriatic Arthritis in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Psoriatic Arthritis in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Psoriatic Arthritis in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Psoriatic Arthritis in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Psoriatic Arthritis in Germany (2016-2028)
Figure 12: Treatable Cases of the Psoriatic Arthritis in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Psoriatic Arthritis in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Psoriatic Arthritis in France (2016-2028)
Figure 15: Sex- Specific Cases of the Psoriatic Arthritis in France (2016-2028)
Figure 16: Diagnosed Cases of the Psoriatic Arthritis in France (2016-2028)
Figure 17: Treatable Cases of the Psoriatic Arthritis in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Psoriatic Arthritis in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Psoriatic Arthritis in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Psoriatic Arthritis in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Psoriatic Arthritis in Italy (2016-2028)
Figure 22: Treatable Cases of the Psoriatic Arthritis in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Psoriatic Arthritis in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Psoriatic Arthritis in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Psoriatic Arthritis in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Psoriatic Arthritis in Spain (2016-2028)
Figure 27: Treatable Cases of the Psoriatic Arthritis in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Psoriatic Arthritis in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Psoriatic Arthritis in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Psoriatic Arthritis in UK (2016-2028)
Figure 31: Diagnosed Cases of the Psoriatic Arthritis in UK (2016-2028)
Figure 32: Treatable Cases of the Psoriatic Arthritis in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Psoriatic Arthritis in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Psoriatic Arthritis in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Psoriatic Arthritis in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Psoriatic Arthritis in Japan (2016-2028)
Figure 37: Treatable Cases of the Psoriatic Arthritis in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 42:7MM- Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 45: United States-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 48: Germany-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 51: France-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 54: Italy-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 57: Spain-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 60:UK-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Psoriatic Arthritis in USD MM (2016-2028)
Figure 63: Japan-Market Share Psoriatic Arthritis by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Psoriatic Arthritis by Therapies in USD MM (2016-2028)

  • Global Ankylosing Spondylitis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Ankylosing Spondylitis market: According to our latest research, the global Ankylosing Spondylitis market looks promising in the next 5 years. As of 2022, the global Ankylosing Spondylitis market was estimated at USD 5633.32 million, and it's anticipated to reach USD 9003.47 million in 2028, with a CAGR of 8.13% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the ......
  • Global Osteoarthritis Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Osteoarthritis Treatment market: According to our latest research, the global Osteoarthritis Treatment market looks promising in the next 5 years. As of 2022, the global Osteoarthritis Treatment market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global......
  • Global Viscosupplementation Market Research Report 2023
    Published: 11-Oct-2023        Price: US 2900 Onwards        Pages: 92
    Viscosupplementation is a medical treatment for knee osteoarthritis during which lubricating fluid is injected into the knee joint to reduce pain symptoms. According to QYResearch's new survey, global Viscosupplementation market is projected to reach US$ 2329.4 million in 2029, increasing from US$ 1822 million in 2022, with the CAGR of 3.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctua......
  • Global Psoriatic Arthritis Market 2023
    Published: 01-Sep-2023        Price: US 3350 Onwards        Pages: 91
    Description The global market for psoriatic arthritis treatment is projected to reach USD 12.72 billion by 2029, growing at a CAGR of 6.1% from USD 8.27 billion in 2022. Psoriatic arthritis is a chronic inflammatory rheumatic disease that affects up to 30% of psoriasis patients aged 30 to 60. It is more common in women. The exact cause is unknown, but family history and certain risk factors play a role. Diagnosis involves imaging techniques and symptom evaluation. Treatment options include......
  • Global Tinea Pedis Treatment Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 114
    Fungal foot-animal, known medically as tinea pedis, is a common skin infection of the feet caused by fungus. Signs and symptoms often include itching, scaling, cracking and redness. In rare cases the skin may blister. Athlete's foot fungus may infect any part of the foot, but most often grows between the toes. In this report, we study the drugs for Fungal foot-animal. The global Tinea Pedis Treatment market is projected to grow from US$ 1230 million in 2023 to US$ 1520.8 mi......
  • Global Osteoarthritis Treatment Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 10-Aug-2023        Price: US 3260 Onwards        Pages: 100
    The Osteoarthritis Treatment market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Osteoarthritis Treatment industry, and breaks down according to the type, application, and consumption area of Osteoarthritis Treatment. The report also introduces players in the industry from the perspective of the industry chain and marketing cha......
  • Global Osteoarthritis Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 01-Aug-2023        Price: US 3260 Onwards        Pages: 102
    The Osteoarthritis market revenue was 7668.26 Million USD in 2022, and will reach 14182.81 Million USD in 2028, with a CAGR of 10.79% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Osteoarthritis industry, and breaks down according to the type, application, and consumption area of Osteoarthritis. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes......
  • Global Viscosupplementation Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 27-Jul-2023        Price: US 3260 Onwards        Pages: 104
    The Viscosupplementation market revenue was 2579.17 Million USD in 2022, and will reach 3483.24 Million USD in 2028, with a CAGR of 5.14% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Viscosupplementation industry, and breaks down according to the type, application, and consumption area of Viscosupplementation. The report also introduces players in the industry from the perspective of the industry chain and marketing cha......
  • Global Ankylosing Spondylitis Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 22-Jun-2023        Price: US 3260 Onwards        Pages: 99
    The Ankylosing Spondylitis market revenue was 5633.32 Million USD in 2022, and will reach 9003.47 Million USD in 2028, with a CAGR of 8.13% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Ankylosing Spondylitis industry, and breaks down according to the type, application, and consumption area of Ankylosing Spondylitis. The report also introduces players in the industry from the perspective of the industry chain and marketi......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs